🟢 ATAI Life Sciences is trading 32% up today as FDA finalizes psychedelic drug development guidance

ATAI Life Sciences is trading 32% higher at $7.08 after the FDA finalized new guidance for psychedelic drug development, reducing regulatory uncertainty for the sector.

• Jefferies noted the guidance signals a more supportive environment for companies advancing psychedelic-based therapies, reinforcing investor optimism toward the regulatory outlook.
• The company is currently advancing BPL-003, a psychedelic-based therapy specifically designed for treatment-resistant depression.